The expansion of its current Belgium plant gives Masthercell, which is a cell therapy-focused contract development and manufacturing organization, five additional state-of-the-art clean rooms. The new wing also includes two development laboratories, a quality control laboratory and additional warehouse capabilities.
Maggie De Block, Belgium’s Public Health and Social Affairs minister, and Willy Borsus, the minister-president of Wallonia were in attendance for the launch of the new facility.
“The cell therapy industry, and specifically our partners, are eager to have access to reliable and additional state-of-the-art facilities for their commercial projects,” said Dr Denis Bedoret, managing director of Masthercell in a statement.
“Our objective is to help them access the market faster with tailor-made capabilities. Today, we are pleased to offer these key assets to our partners and more widely to any cell therapy company facing a lack of production or development capacities,” Bedoret added.
Masthercell is also backed by Great Point Partners LLC, a healthcare investment firm based in Greenwich, Connecticut.
Orgenesis is a biopharmaceutical company focused on cell-therapy development and support services.
Via its Masthercell Global subsidiary, Orgenesis works with cell therapy organizations to provide business modeling as well as help with manufacturing and technology selection in a bid to speed up the arrival of their therapies to the market.
Each clean room of the new production wing is 30 square meters and boasts independent HVAC systems while the new production wing is 600 square meters.
Orgenesis shares jumped 9.1% to finish Thursday at $6.23.